Karman Stock Is Up 60%-Plus, but 21x-28x Sales Make the Rally Look Expensive

The rally put KRMN in focus, but valuation now dominates the story

KRMN is no longer a hidden aerospace name. It is increasingly an expectations trade. The stock has gained 64% over the past 3 months, while year-to-date performance is cited at roughly 126% in one measure and 180% in another. That kind of move forces attention, but it also pulls valuation to the center of the debate.

Why investors are willing to pay up

Bulls argue this is more than momentum. Karman sits deep in the defense and space supply chain, supplying mission-critical pieces to primes and government programs, often through long program-based contracts and repeat orders. In that environment, being hard to replace can support a richer multiple.

Why the multiple still looks stretched

Bears see a stock where sentiment is running ahead of proof. In one recent view, shares trade at about 21x sales; in another, at 28.4x price-to-sales. Both figures sit far above typical aerospace and defense levels, which suggests the market is paying for a significant growth step-change before that outcome is fully settled.

After this rally, KRMN looks less like a value setup and more like an execution test. If results keep pace, the premium can hold. If momentum fades before earnings do, the multiple can compress quickly.

Why investors are paying up: Karman sits in a strategic pocket of the supply chain

The niche can support a premium - at least in theory

The market is not valuing Karman like a standard industrial parts maker. It is paying for positioning inside defense and space programs, where reliability, qualification, and engineering know-how matter more than low-cost mass production.

Karman makes mission-critical pieces such as propulsion hardware, thermal protection, and deployable structures for rockets, missiles, satellites, and other defense and space hardware. Its main customers are primes, government programs, and space companies that buy to strict specifications. Add in in-house capabilities in engineering, design, analysis, testing, qualification, and manufacturing, and the business looks less like a commodity manufacturer and more like a specialized enabler for programs that cannot easily afford to switch suppliers.

That does not guarantee a rich multiple, but it helps explain why investors are willing to pay above normal industrial levels for exposure to this part of the supply chain.

The valuation debate is about expectations, not defensibility

The real question is no longer whether Karman has a defensible position. The cited evidence supports that case. The harder question is whether that position can justify a sales multiple that high through a cycle, not just during a momentum-heavy stretch.

The market is pricing in more than current results

Two recent snapshots show how extreme that pricing is: about 21x sales in one view and 28.4x price-to-sales in another. Those are not normal aerospace multiples. They imply investors expect more than steady growth.

The earnings math tells a similar story. Karman's 12-month average P/E ratio of 530.62 is well above its P/E ratio as of Jul. 10, 2026 of 220.99. That gap exists because trailing earnings were much thinner earlier in the year. As profitability improves, the trailing P/E can fall without any change in stock price. Even so, a high multiple still signals that the market is paying for growth that is improving rather than fully proven.

Why execution matters more now

Bulls can reasonably point to program barriers: Karman supplies mission-critical pieces to primes and government programs, often through long program-based contracts and repeat orders, while offering engineering, design, analysis, testing, qualification, and manufacturing under one roof. In that setting, switching can be difficult, and scarcity can support richness.

But at this valuation, the bear case is straightforward: a high sales multiple can survive on narrative for a while, yet it still depends on execution. If backlog conversion, margin durability, or program visibility disappoint, investors are likely to reprice the stock faster than they cheered it.

Key signals to watch:

• revenue conversion from program wins
• whether margins expand with scale
• whether backlog visibility remains clear quarter over quarter

If those factors improve together, the premium becomes easier to defend. If not, the market may quickly shift from rewarding scarcity to discounting delayed proof.

What could justify the premium - or break the momentum

There is at least one structural watchpoint alongside operating results. After the IPO, affiliates of Trive Capital retained majority voting power, making Karman a controlled company that relies on exemptions from certain NYSE corporate governance standards. That does not invalidate the investment case, but it does mean less board-level check-and-balance if execution wobbles.

Until earnings and backlog conversion catch up with the stock's move, KRMN looks more like a high-expectation growth trade than a bargain-basement value stock.